207386-63-8

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 122-37-2 4-anilinophenol 

Downstream Products

• 1448525-91-4 N-(4-hydroxyphenyl)-3-{6-[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide hydrochloride 
• 1007561-00-3 4-bromo-N-(4-(tert-butyldimethylsilyloxy)-phenyl)-N-phenylbenzenamine 
• 1253294-02-8 2-(4-(N-phenyl-N-(4-(tert-butyldimethylsilyloxy)phenyl)amino)phenyl)-3,4-ethylenedioxythiophene 
• 1253294-00-6 2-(4-(N-phenyl-N-(4-(tert-butyldimethylsilyloxy)phenylamino))phenyl)thiophene 

Relevant academic research and scientific papers

Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same

The invention relates to compounds of formula (I), wherein Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, T and W are as defined in the description. The invention also relates to drugs containing same.

New indolizine compound, preparation method thereof and pharmaceutical compositions containing them (by machine translation)

The invention of the formula (I) compound, Wherein R a, R b, R c, R d, T, R 3, R 4, R 5, X, Y and Het as defined in the description. The invention also relates to a medicament containing the above-mentioned compounds. (by machine translation)

INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, T and W are as defined in the description. Medicinal products containing the same whic

INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I) wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

PHOSPHATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein X, Y, A1, A2, Ra, Rb, Rc, Rd, R3, R4, T and R5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Pure and saturated red electroluminescent polyfluorenes with dopant/host system and PLED efficiency/color purity trade-offs

Three kinds of red electroluminescent (EL) polymers based on polyfluorene as blue host and 2,1,3-benzothiadiazole derivatives with different emission wavelengths as red dopant units on the side chain are designed and synthesized. The influence of the photoluminescence (PL) efficiencies and emission wavelengths of red dopants on the EL efficiencies and color purities of the resulting polyfluorene copolymers of dopant/host system is investigated by adjusting the electron donating ability of the donor units in D-;r-A-D typed 2,1,3-benzothiadiazole derivatives. The devices of these red-emitting polymers realize remarkable EL efficiency/color purity trade-offs. The single-layer devices with the configuration of ITO/PEDOT:PSS/Polymer/Ca/Al show pure red emission at 624 nm with a luminous efficiency of 3.83 cd A-1 and CIE of (0.63, 0.35) for PFR1, saturated red emission at 636 nm with a luminous efficiency of 2.29 cd A-1 and CIE of (0.64, 0.33) for PFR2, respectively. By introduction of an additional electron injection layer PF-EP(Ethanol soluble phosphonate-functionalized polyfluorene), high performance pure and saturated red emission two-layer devices (ITO/PEDOT:PSS/Polymer/PF-EP/ LiF/ Al) were achieved with maximum luminous efficiencies of 5.50 cd A -1 and CIE of (0.62, 0.35) for PFR1, 3.10 cd A-1 and CIE of (0.63, 0.33) for PFR2, respectively, which are the best results for pure and saturated fluorescent red EL polymers reported so far.